YK
Therapeutic Areas
PeLeMed Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PLD-102 | FLT3‑mutant AML | Phase 1 |
| PLD-103 | YAP‑TEAD driven cancers | Preclinical |
| PLD-104 | RET‑mutant NSCLC | Preclinical |
| PLD-105 | PD‑1 non‑responding solid tumors | Preclinical |
| PLD-106 | Renal cell carcinoma & hepatocellular carcinoma | Preclinical |
| PLD-107 | ADC for AML & solid tumors | Preclinical |
| PLM-401/402 | Chronic hepatitis B virus | Preclinical |